Daiichi Sankyo And Merck Announce First Patient Dosed In Phase 3 IDeate-Lung02 Trial Evaluating Ifinatamab Deruxtecan For Relapsed Small Cell Lung Cancer Versus Chemotherapy
Portfolio Pulse from Benzinga Newsdesk
Daiichi Sankyo and Merck have announced the dosing of the first patient in the Phase 3 IDeate-Lung02 trial. This trial is evaluating Ifinatamab Deruxtecan for relapsed small cell lung cancer compared to chemotherapy.
August 01, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck, in collaboration with Daiichi Sankyo, has dosed the first patient in a Phase 3 trial for Ifinatamab Deruxtecan, targeting relapsed small cell lung cancer.
The initiation of a Phase 3 trial is a significant milestone in drug development. Positive results could lead to a new treatment option for relapsed small cell lung cancer, potentially boosting Merck's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80